Lindbrook Capital, LLC Cardiff Oncology, Inc. Transaction History

Lindbrook Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 18, 2022	SELL	$5.18 - $7.24 $8,806 - $12,308	-1,700 Closed	0 $0
Q2 2021 Jul 27, 2021	BUY	$6.65 - $10.04 $6,650 - $10,040	1,000 Added 142.86%	1,700 $11,000
Q1 2021 Apr 28, 2021	BUY	$9.1 - $19.57 $6,370 - $13,699	700 New	700 $6,000
Q4 2020 Jan 27, 2021	SELL	$12.02 - $24.71 $6,010 - $12,355	-500 Closed	0 $0
Q3 2020 Nov 03, 2020	BUY	$4.25 - $14.19 $2,125 - $7,095	500 New	500 $7,000

12.1M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $148M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.